Phase II Study of Cabazitaxel-XRP6258 in Advanced Non-Small Cell Lung Cancer

NCT01438307 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)
Stage IV NSCLC
Metastatic NSCLC

Interventions

DRUG: Cabazitaxel-XRP6258 (3-week cycle)
DRUG: Cabazitaxel-XRP6258 (5-week cycle)

Sponsor

University of Alabama at Birmingham

Collaborators

[object Object]